Literature DB >> 12970082

Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism.

S Akerman1, D J Williamson, P J Goadsby.   

Abstract

Amissense mutation of the CACNA1A gene that encodes the alpha1A subunit of the voltage-dependent P/Q-type calcium channel has been discovered in patients suffering from familial hemiplegic migraine. This suggested that calcium channelopathies may be involved in migraine more broadly, and established the importance of genetic mechanisms in migraine. Channelopathies share many clinical characteristics with migraine, and thus exploring calcium channel functions in the trigeminovascular system may give insights into migraine pathophysiology. It is also known that drugs blocking the P/Q- and N-type calcium channels have been successful in other animal models of trigeminovascular activation and head pain. In the present study, we used intravital microscopy to examine the effects of specific calcium channel blockers on neurogenic dural vasodilatation and calcitonin gene-related peptide (CGRP)-induced dilation. The L-type voltage-dependent calcium channel blocker calciseptine significantly attenuated (20 microg kg(-1), n=7) the dilation brought about by electrical stimulation, but did not effect CGRP-induced dural dilation. The P/Q-type voltage-dependent calcium channel blocker omega-agatoxin-IVA (20 microg kg-1, n=7) significantly attenuated the dilation brought about by electrical stimulation, but did not effect CGRP-induced dural dilation. The N-type voltage-dependent calcium channel blocker omega-conotoxin-GVIA (20 microg kg(-1), n=8 and 40 microg kg(-1), n=7) significantly attenuated the dilation brought about by electrical stimulation, but did not effect CGRP-induced dural dilation. It is thought that the P/Q-, N- and L-type calcium channels all exist presynaptically on trigeminovascular neurons, and blockade of these channels prevents CGRP release, and, therefore, dural blood vessel dilation. These data suggest that the P/Q-, N- and L-type calcium channels may be involved in trigeminovascular nociception.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970082      PMCID: PMC1574049          DOI: 10.1038/sj.bjp.0705456

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  54 in total

1.  N- and L- but not P/Q-type calcium channels contribute to neuropeptide release from rat skin in vitro.

Authors:  M Kress; I Izydorczyk; A Kuhn
Journal:  Neuroreport       Date:  2001-03-26       Impact factor: 1.837

2.  Immunohistochemical study on the distribution of the voltage-gated calcium channel alpha(1B) subunit in the mature rat brain.

Authors:  Y H Chung; C Shin; K H Park; C I Cha
Journal:  Brain Res       Date:  2000-06-02       Impact factor: 3.252

3.  Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia.

Authors:  R Uddman; J Tajti; S Möller; F Sundler; L Edvinsson
Journal:  Brain Res       Date:  1999-05-01       Impact factor: 3.252

4.  Distribution of the voltage-dependent calcium channel alpha(1A) subunit throughout the mature rat brain and its relationship to neurotransmitter pathways.

Authors:  P J Craig; A D McAinsh; A L McCormack; W Smith; R E Beattie; J V Priestley; J L Yip; S Averill; E R Longbottom; S G Volsen
Journal:  J Comp Neurol       Date:  1998-07-27       Impact factor: 3.215

5.  Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist.

Authors:  M J Cumberbatch; D J Williamson; G S Mason; R G Hill; R J Hargreaves
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

6.  Voltage-dependent sodium and calcium currents in acutely isolated adult rat trigeminal root ganglion neurons.

Authors:  H C Kim; M K Chung
Journal:  J Neurophysiol       Date:  1999-03       Impact factor: 2.714

7.  Functional embryonic cardiomyocytes after disruption of the L-type alpha1C (Cav1.2) calcium channel gene in the mouse.

Authors:  C Seisenberger; V Specht; A Welling; J Platzer; A Pfeifer; S Kühbandner; J Striessnig; N Klugbauer; R Feil; F Hofmann
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

8.  Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.

Authors:  P J Goadsby; L Edvinsson; R Ekman
Journal:  Ann Neurol       Date:  1990-08       Impact factor: 10.422

9.  alpha-eudesmol, a P/Q-type Ca(2+) channel blocker, inhibits neurogenic vasodilation and extravasation following electrical stimulation of trigeminal ganglion.

Authors:  K Asakura; T Kanemasa; K Minagawa; K Kagawa; T Yagami; M Nakajima; M Ninomiya
Journal:  Brain Res       Date:  2000-08-04       Impact factor: 3.252

10.  Presynaptic L-type Ca(2)+ channels on excessive dopamine release from rat caudate putamen.

Authors:  M Okita; Y Watanabe; K Taya; H Utsumi; T Hayashi
Journal:  Physiol Behav       Date:  2000-03
View more
  20 in total

1.  A PEPTIDE UNCOUPLING CRMP-2 FROM THE PRESYNAPTIC Ca(2+) CHANNEL COMPLEX DEMONSTRATES EFFICACY IN ANIMAL MODELS OF MIGRAINE AND AIDS THERAPY-INDUCED NEUROPATHY.

Authors:  Matthew S Ripsch; Carrie J Ballard; May Khanna; Joyce H Hurley; Fletcher A White; Rajesh Khanna
Journal:  Transl Neurosci       Date:  2012-03       Impact factor: 1.757

Review 2.  Headache-type adverse effects of NO donors: vasodilation and beyond.

Authors:  G Bagdy; P Riba; V Kecskeméti; D Chase; G Juhász
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

3.  Calcitonin gene-related peptide enhances release of native brain-derived neurotrophic factor from trigeminal ganglion neurons.

Authors:  Ilya Buldyrev; Nathan M Tanner; Hui-ya Hsieh; Emily G Dodd; Loi T Nguyen; Agnieszka Balkowiec
Journal:  J Neurochem       Date:  2006-10-25       Impact factor: 5.372

4.  Riboflavin and vitamin E increase brain calcium and antioxidants, and microsomal calcium-ATP-ase values in rat headache models induced by glyceryl trinitrate.

Authors:  Ayşe Bütün; Mustafa Nazıroğlu; Serpil Demirci; Ömer Çelik; Abdulhadi Cihangir Uğuz
Journal:  J Membr Biol       Date:  2014-11-26       Impact factor: 1.843

Review 5.  Insights into migraine mechanisms and CaV2.1 calcium channel function from mouse models of familial hemiplegic migraine.

Authors:  Daniela Pietrobon
Journal:  J Physiol       Date:  2010-03-01       Impact factor: 5.182

6.  Topiramate inhibits trigeminovascular activation: an intravital microscopy study.

Authors:  Simon Akerman; Peter J Goadsby
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

Review 7.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 8.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

9.  Resolution of Persistent Post-Stapedotomy Vertigo With Migraine Prophylactic Medication.

Authors:  Omid Moshtaghi; Hossein Mahboubi; Yarah M Haidar; Ronald Sahyouni; Harrison W Lin; Hamid R Djalilian
Journal:  Otol Neurotol       Date:  2017-12       Impact factor: 2.311

10.  The proteome of mouse cerebral arteries.

Authors:  AmanPreet Badhwar; Danica B Stanimirovic; Edith Hamel; Arsalan S Haqqani
Journal:  J Cereb Blood Flow Metab       Date:  2014-03-26       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.